T CELL RECEPTORS TARGETING THE HIGHLY PREVALENT KRAS G12C MUTATION ON HLA-A03:01 IN LUNG CANCER

T CELL RECEPTORS TARGETING THE HIGHLY PREVALENT KRAS G12C MUTATION ON HLA-A03:01 IN LUNG CANCER

The present disclosure is directed to recombinant T-cell Receptors (TCRs) that binds Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) protein comprising a G12C mutation presented on a human leucocyte antigen-A (HLA-A)*03:01, polynucleotides encoding such TCRs, engineered T-cells comprising such TCR...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: LIZEE, Gregory A, REUBEN, Alexandre, HEYMACH, John Victor, ZHANG, Minying, JIANG, Peixin
Format: Patent
Sprache:eng ; fre
Schlagworte:
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The present disclosure is directed to recombinant T-cell Receptors (TCRs) that binds Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) protein comprising a G12C mutation presented on a human leucocyte antigen-A (HLA-A)*03:01, polynucleotides encoding such TCRs, engineered T-cells comprising such TCRs, and methods of using the same. La présente invention concerne des récepteurs de lymphocytes T (TCR) recombinants qui se lient à une protéine de l'homologue de l'oncogène viral du sarcome du rat de Kirsten (KRAS) comprenant une mutation G12C présentée sur un antigène leucocytaire humain A (HLA-A)*03:01, des polynucléotides codant pour de tels TCR, des lymphocytes T modifiés comprenant de tels TCR, et des procédés d'utilisation de ceux-ci.